Compounds > nelfinavir
Page last updated: 2024-08-24

nelfinavir and N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide

nelfinavir has been researched along with N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chia, CSB; Shuyi Ng, P; Xu, W1

Reviews

1 review(s) available for nelfinavir and N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide

ArticleYear
A Patent Review on SARS Coronavirus Main Protease (3CL
    ChemMedChem, 2022, 01-05, Volume: 17, Issue:1

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Humans; Patents as Topic; Protein Conformation; Structure-Activity Relationship

2022